Collection of Samples From HIV-1 Infected Individuals for Evaluation of the Aptima HIV-1 Assay
Status: | Completed |
---|---|
Conditions: | HIV / AIDS, HIV / AIDS |
Therapuetic Areas: | Immunology / Infectious Diseases |
Healthy: | No |
Age Range: | 15 - Any |
Updated: | 2/24/2017 |
Start Date: | January 2014 |
End Date: | January 2017 |
Collection of Plasma Samples From Human Immunodeficiency Virus (HIV) Type 1 (HIV-1) Infected Individuals for the Clinical Evaluation of the Aptima HIV-1 Quant Dx Assay
The objective is to obtain plasma samples from Human Immunodeficiency Virus Type 1 (HIV-1)
infected individuals that have viral loads across the dynamic range of the Aptima HIV-1
assay. The plasma samples will be tested in a method comparison study to support the
approval of the Aptima HIV-1 assay on Gen-Probe's Panther testing system. The objective of
the method comparison study is to evaluate the clinical utility of the Aptima HIV-1 assay by
comparing the results to the FDA-licensed COBAS assay (Roche Molecular Systems, Inc.,
Branchburg, New Jersey) in plasma samples that have viral loads across the dynamic range of
the Aptima HIV-1 assay.
infected individuals that have viral loads across the dynamic range of the Aptima HIV-1
assay. The plasma samples will be tested in a method comparison study to support the
approval of the Aptima HIV-1 assay on Gen-Probe's Panther testing system. The objective of
the method comparison study is to evaluate the clinical utility of the Aptima HIV-1 assay by
comparing the results to the FDA-licensed COBAS assay (Roche Molecular Systems, Inc.,
Branchburg, New Jersey) in plasma samples that have viral loads across the dynamic range of
the Aptima HIV-1 assay.
Inclusion Criteria
- The subject has documented HIV infection
- The subject is at least 15 years of age at the time of enrollment
- For ART subjects, subject has documented HIV-1 RNA levels above the lower limit of
quantitation of an FDA-approved assay in a sample collected in the past 90 days.
- The subject (and/or legally authorized representative, if allowed) is willing and
able to provide written informed consent before providing a specimen (a minor will
need the documented consent of his/her parent or legal guardian, unless the site has
an institutional review board [IRB]-approved waiver for parental consent for minors).
Exclusion Criteria
- A potential subject will be ineligible for the study if the subject, clinician, or
medical record reports any of the following:
- Subject's HIV disease stage and/or current ART status is unknown.
- It is unknown if current or previous ART was changed or stopped due to therapy
failure.
- For non-ART subjects, subject was previously on ART in the past 30 days
- Subject already participated in this study and subject's previous sample(s) was
provided and not withdrawn (ie, subject has an evaluable sample in the study)
- Subject has a history of illness that the principal investigator (PI) or designee
considers could interfere with or affect the conduct, results, and/or completion of
the study
- Subject has a history of illness that the PI or designee considers could create an
unacceptable risk to the subject if enrolled in the study
We found this trial at
9
sites
Jacobi Medical Center In 1955, the NYC Department of Hospitals opened a new, specialized care...
Click here to add this to my saved trials
Johns Hopkins University The Johns Hopkins University opened in 1876, with the inauguration of its...
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Yale University Yale's roots can be traced back to the 1640s, when colonial clergymen led...
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials